BioSpace News Archive

XORTX Therapeutics Inc. (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a synopsis of 2020 achievements and guidance on key activities for 2021.

As previously reported on December 7, 2020 preliminary results achieved during the feasibility studies indicated a test sensitivity of 80% and a specificity of over 90% for Therma’s CoviSafe™.

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) (“CVR Medical” or the “Company” or “we”) a Canadian listed and US-based healthcare company in the medical device market is pleased to announce Michael Rhodes as Chief Executive Officer (CEO).

The research report on ‘global wireless brain sensor market’ offers substantial information concerning this business vertical in terms of growth stimulants, hindering factors, and other expansion trends which are likely to impact the dynamics of this business domain.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $1 million programmatic investment in Satellos Bioscience Inc. (Satellos) to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne.

Manufacturing Growth Expected in 2021; Revenue to Increase 6.9%; Capital Expenditures to Increase 2.4%; Capacity Utilization Currently at 85.7%; Services Growth Projected in 2021; Revenue to Increase 1.6%; Capital Expenditures to Increase 12.7%: Capacity Utilization Currently at 86.6%

Expansion of the geriatric patient population affected by various eye-related diseases, pushing the need for surgeries will amplify the adoption of ophthalmic devices.

The North America self-monitoring blood glucose devices market is poised for remarkable expansion due to the increasing adoption of unhealthy and detrimental dietary habits, alongside the physically inactive lifestyles resulting in the growth of obese populace.

Celdara Medical, LLC announced that the National Institute of Allergy and Infectious Disease of the National Institutes of Health has awarded it a two-year Small Business Technology Transfer Research grant to fund the development of a novel, broad-spectrum therapeutic/prophylactic against RNA viruses, including SARS-CoV-2, SARS, Ebola, influenza, and pathogenic arenaviruses.

Abram Scientific today announced it has secured a $2.9 million US Army Grant in support of the company’s effort to address the COVID-19 pandemic. This grant supports the clinical development of the CoagCare System to screen for COVID-19 related blood clotting disorders or coagulopathies in patients. The CoagCare System is intended